Cargando…

Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?

Background: Detection of variants of uncertain significance (VUSs) in BRCA1 and BRCA2 genes poses relevant challenges for counseling and managing patients. VUS carriers should be managed similarly to probands with no BRCA1/2 variants detected, and predictive genetic testing in relatives is discourag...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuntini, Roberta, Ferrari, Simona, Bonora, Elena, Buscherini, Francesco, Bertonazzi, Benedetta, Grippa, Mina, Godino, Lea, Miccoli, Sara, Turchetti, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141711/
https://www.ncbi.nlm.nih.gov/pubmed/30254663
http://dx.doi.org/10.3389/fgene.2018.00378
_version_ 1783355754758012928
author Zuntini, Roberta
Ferrari, Simona
Bonora, Elena
Buscherini, Francesco
Bertonazzi, Benedetta
Grippa, Mina
Godino, Lea
Miccoli, Sara
Turchetti, Daniela
author_facet Zuntini, Roberta
Ferrari, Simona
Bonora, Elena
Buscherini, Francesco
Bertonazzi, Benedetta
Grippa, Mina
Godino, Lea
Miccoli, Sara
Turchetti, Daniela
author_sort Zuntini, Roberta
collection PubMed
description Background: Detection of variants of uncertain significance (VUSs) in BRCA1 and BRCA2 genes poses relevant challenges for counseling and managing patients. VUS carriers should be managed similarly to probands with no BRCA1/2 variants detected, and predictive genetic testing in relatives is discouraged. However, miscomprehension of VUSs is common and can lead to inaccurate risk perception and biased decisions about prophylactic surgery. Therefore, efforts are needed to improve VUS evaluation and communication at an individual level. Aims: We aimed at investigating whether cosegregation analysis, integrated with a careful review of available functional data and in silico predictions, may improve VUSs interpretation and counseling in individual families. Methods: Patients with Breast Cancer (BC) and/or Ovarian Cancer (OC) fulfilling established criteria were offered genetic counseling and BRCA1/2 testing; VUSs identified in index cases were checked in other relatives affected by BC/OC whenever possible. As an alternative, if BC/OC clustered only in one branch of the family, the parental origin of the VUS was investigated. Public prediction tools and databases were used to collect additional information on the variants analyzed. Results: Out of 1045 patients undergoing BRCA1/2 testing in the period October 2011–April 2018, 66 (6.3%) carried class 3 VUSs. Cosegregation analysis was performed for 13 VUSs in 11 kindreds. Seven VUSs (53.8%) did not cosegregate with breast/ovarian cancer in the family, which provided evidence against their role in cancer clustering in those families. Among the 6 cosegregating VUSs, for two (BRCA1 c.5152+2T>G and BRCA2 c.7975A>G) additional evidence exists from databases and in silico tools supporting their pathogenicity, which reinforces the hypothesis they may have had a predisposing effect in respective families. For the remaining four VUSs (31%), cosegregation analysis failed to provide relevant information. Conclusion: Our findings suggest that cosegregation analysis in a clinical context may be helpful to improve test result interpretation in the specific family and, therefore, should be offered whenever possible. Besides, obtaining and sharing cosegregation data helps gathering evidence that may eventually contribute to VUS classification.
format Online
Article
Text
id pubmed-6141711
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61417112018-09-25 Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help? Zuntini, Roberta Ferrari, Simona Bonora, Elena Buscherini, Francesco Bertonazzi, Benedetta Grippa, Mina Godino, Lea Miccoli, Sara Turchetti, Daniela Front Genet Genetics Background: Detection of variants of uncertain significance (VUSs) in BRCA1 and BRCA2 genes poses relevant challenges for counseling and managing patients. VUS carriers should be managed similarly to probands with no BRCA1/2 variants detected, and predictive genetic testing in relatives is discouraged. However, miscomprehension of VUSs is common and can lead to inaccurate risk perception and biased decisions about prophylactic surgery. Therefore, efforts are needed to improve VUS evaluation and communication at an individual level. Aims: We aimed at investigating whether cosegregation analysis, integrated with a careful review of available functional data and in silico predictions, may improve VUSs interpretation and counseling in individual families. Methods: Patients with Breast Cancer (BC) and/or Ovarian Cancer (OC) fulfilling established criteria were offered genetic counseling and BRCA1/2 testing; VUSs identified in index cases were checked in other relatives affected by BC/OC whenever possible. As an alternative, if BC/OC clustered only in one branch of the family, the parental origin of the VUS was investigated. Public prediction tools and databases were used to collect additional information on the variants analyzed. Results: Out of 1045 patients undergoing BRCA1/2 testing in the period October 2011–April 2018, 66 (6.3%) carried class 3 VUSs. Cosegregation analysis was performed for 13 VUSs in 11 kindreds. Seven VUSs (53.8%) did not cosegregate with breast/ovarian cancer in the family, which provided evidence against their role in cancer clustering in those families. Among the 6 cosegregating VUSs, for two (BRCA1 c.5152+2T>G and BRCA2 c.7975A>G) additional evidence exists from databases and in silico tools supporting their pathogenicity, which reinforces the hypothesis they may have had a predisposing effect in respective families. For the remaining four VUSs (31%), cosegregation analysis failed to provide relevant information. Conclusion: Our findings suggest that cosegregation analysis in a clinical context may be helpful to improve test result interpretation in the specific family and, therefore, should be offered whenever possible. Besides, obtaining and sharing cosegregation data helps gathering evidence that may eventually contribute to VUS classification. Frontiers Media S.A. 2018-09-11 /pmc/articles/PMC6141711/ /pubmed/30254663 http://dx.doi.org/10.3389/fgene.2018.00378 Text en Copyright © 2018 Zuntini, Ferrari, Bonora, Buscherini, Bertonazzi, Grippa, Godino, Miccoli and Turchetti. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zuntini, Roberta
Ferrari, Simona
Bonora, Elena
Buscherini, Francesco
Bertonazzi, Benedetta
Grippa, Mina
Godino, Lea
Miccoli, Sara
Turchetti, Daniela
Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title_full Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title_fullStr Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title_full_unstemmed Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title_short Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?
title_sort dealing with brca1/2 unclassified variants in a cancer genetics clinic: does cosegregation analysis help?
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141711/
https://www.ncbi.nlm.nih.gov/pubmed/30254663
http://dx.doi.org/10.3389/fgene.2018.00378
work_keys_str_mv AT zuntiniroberta dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT ferrarisimona dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT bonoraelena dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT buscherinifrancesco dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT bertonazzibenedetta dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT grippamina dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT godinolea dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT miccolisara dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp
AT turchettidaniela dealingwithbrca12unclassifiedvariantsinacancergeneticsclinicdoescosegregationanalysishelp